Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Rhea-AI Summary

Nektar Therapeutics (NASDAQ:NKTR) has scheduled an investor call and webcast for June 24, 2025, at 8:15 AM ET to present top-line data from the 16-week induction period of their Phase 2b REZOLVE-AD clinical trial. The study evaluates rezpegaldesleukin, a regulatory T-cell proliferator, for treating moderate-to-severe atopic dermatitis.

The data will be released via press release on the morning of the call, with webcast access details to be provided through the company's website. A replay will be available for at least 30 days after the event.

News Market Reaction – NKTR

+156.29%

1 alert

+156.29% News Effect

On the day this news was published, NKTR gained 156.29%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT.

The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at www.nektar.com. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:

Corey Davis, PhD
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

For Media:

Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-top-line-data-from-the-16-week-induction-period-in-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-a-regulatory-t-cell-proliferator-in-atopic-dermatitis-on-june-24-2025-302488592.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) announce the REZOLVE-AD Phase 2b trial results?

Nektar will announce the results on June 24, 2025 at 8:15 AM ET through an investor call and webcast.

What is the purpose of Nektar's REZOLVE-AD Phase 2b trial?

The trial evaluates rezpegaldesleukin, a regulatory T-cell proliferator, for the treatment of moderate-to-severe atopic dermatitis.

How can investors access Nektar's REZOLVE-AD trial data presentation?

Investors can access the presentation through a live webcast with details to be provided in the morning press release and on www.nektar.com.

How long will the replay of Nektar's Phase 2b data presentation be available?

The webcast replay will be available for at least 30 days following the event.